Código QR

Baseline symptom profile does not predict early response to electroconvulsive therapy (ECT) in major depressive disorder (MDD)

Guardado en:

Detalles Bibliográficos
Autores principales:	Bijan Zarrabi, Steve Seiner, Shan Siddiqi
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
Acceso en línea:	https://doaj.org/article/3c81e186e96a4defb9129322b08cdc07
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

The Association Between Hypoxia Improvement and Electroconvulsive Therapy for Major Depressive Disorder
por: Bian Z, et al.
Publicado: (2021)

The Relationship Between Baseline Clinical Symptom Characteristics and Working Ability in Japanese Patients Treated for Major Depressive Disorder and Painful Physical Symptoms
por: Sugawara N, et al.
Publicado: (2020)

Identifying Resonant Frequencies for Treatment of Major Depressive Disorder (MDD) using repetitive Transcranial Magnetic Stimulation (rTMS)
por: Juliana Corlier, et al.
Publicado: (2021)

PTSD comorbidities in patients undergoing ECT for major depressive disorder: a national study across the United States
por: Nagy Youssef, et al.
Publicado: (2021)

Electroconvulsive therapy treatment in patients with somatic symptom and related disorders
por: Leong KW, et al.
Publicado: (2015)

Possible Hypothetical Mode of Action of ECT (Electroconvulsive Therapy) Based on DNA Dipole Character and Epigenetics
por: Koch H. J.
Publicado: (2021)

Levels of serum immunomodulators and alterations with electroconvulsive therapy in treatment-resistant major depression
por: Zincir S, et al.
Publicado: (2016)

Connectome-targeted neuromodulation across symptoms and disorders
por: Shan Siddiqi
Publicado: (2021)

Baseline rumination levels as a predictor of response to repetitive transcranial magnetic stimulation in major depressive disorder
por: Tian Ren Chu, et al.
Publicado: (2021)

Associations of serum cystatin C with depressive symptoms and suicidal ideation in major depressive disorder
por: Ting Sun, et al.
Publicado: (2021)

The prognosis and changes of regional brain gray matter volume in MDD with gastrointestinal symptoms
por: Liu P, et al.
Publicado: (2019)

Prescribing Pharmacotherapy for Major Depressive Disorder: How Does a Clinician Decide?
por: Fiammetta Cosci, et al.
Publicado: (2021)

Residual symptoms in patients with partial versus complete remission of a major depressive disorder episode: patterns of painful physical symptoms in depression
por: Harada E, et al.
Publicado: (2016)

Association between toll-like receptor 4 expression and symptoms of major depressive disorder
por: Wu MK, et al.
Publicado: (2015)

Real world evidence of age-independent electroconvulsive therapy efficacy: a retrospective cohort study
por: James Luccarelli, et al.
Publicado: (2021)

Early symptom non-improvement and aggravation are associated with the treatment response to SSRIs in MDD: a real-world study
por: Yuan H, et al.
Publicado: (2019)

Relationship between initial self-perceived depressive symptoms and disease severity in working patients with first-onset major depressive disorder.
por: Tomoyuki Hirota, et al.
Publicado: (2021)

Comparison of duloxetine and SSRI as a treatment option of painful physical symptoms associated with major depressive disorder
por: Haider M, et al.
Publicado: (2017)

A review of ketamine’s role in ECT and non-ECT settings
por: Jankauskas V, et al.
Publicado: (2018)

Desvenlafaxine in the treatment of major depressive disorder
por: Maria Teresa C Lourenco1, et al.
Publicado: (2009)

Effect of depressive symptom and depressive disorder on glaucoma incidence in elderly
por: Younhea Jung, et al.
Publicado: (2021)

Quantitative ictal electroencephalography (qEEG) comparison of Focal Electrically-Administered Seizure Therapy (FEAST) and Ultrabrief Pulse Right Unilateral Electroconvulsive Therapy (UBP-RUL ECT)
por: Kevin Caulfield, et al.
Publicado: (2021)

Shared and Distinct Fractional Amplitude of Low-Frequency Fluctuation Patterns in Major Depressive Disorders With and Without Gastrointestinal Symptoms
por: Xiaoya Fu, et al.
Publicado: (2021)

Potential Genetic Overlap Between Insomnia and Sleep Symptoms in Major Depressive Disorder: A Polygenic Risk Score Analysis
por: Lindsay M. Melhuish Beaupre, et al.
Publicado: (2021)

The predictive value of somatic and cognitive depressive symptoms for cytokine changes in patients with major depression
por: Dannehl K, et al.
Publicado: (2014)

Psychiatric comorbidities in patients with major depressive disorder
por: Thaipisuttikul P, et al.
Publicado: (2014)

Predictors of Major Depressive Disorder in Older People
por: Susana Sousa, et al.
Publicado: (2021)

Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies
por: Thase ME, et al.
Publicado: (2018)

Structural MRI at 7T reveals amygdala nuclei and hippocampal subfield volumetric association with Major Depressive Disorder symptom severity
por: S. S. G. Brown, et al.
Publicado: (2019)

Symptoms of major depressive disorder during the COVID-19 pandemic: results from a representative sample of the Canadian population
por: Margot Shields, et al.
Publicado: (2021)

Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine
por: Borjanka Batinic, et al.
Publicado: (2021)

Relationship of Subjective Cognitive Impairment with Psychosocial Function and Relapse of Depressive Symptoms in Patients with Major Depressive Disorder: Analysis of Longitudinal Data from PERFORM-J
por: Sumiyoshi T, et al.
Publicado: (2021)

Severity of Depressive Symptoms is Associated with Venous Thromboembolism in Hospitalized Patients with a Major Depressive Episode
por: Yoshizawa K, et al.
Publicado: (2021)

Disturbances of mitochondrial parameters to distinguish patients with depressive episode of bipolar disorder and major depressive disorder
por: Zvěřová M, et al.
Publicado: (2019)

The change of gut microbiota in MDD patients under SSRIs treatment
por: Yang Shen, et al.
Publicado: (2021)

Plasma proteomic data in bipolar II disorders and major depressive disorders
por: Hyunju Lee, et al.
Publicado: (2021)

Does early improvement in depressive symptoms predict subsequent remission in patients with depression who are treated with duloxetine?
por: Sueki A, et al.
Publicado: (2016)

Patient-reported depression severity and cognitive symptoms as determinants of functioning in patients with major depressive disorder: a secondary analysis of the 2-year prospective PERFORM study
por: Haro JM, et al.
Publicado: (2019)

An observational study of duloxetine versus SSRI monotherapy in Japanese patients with major depressive disorder: subgroup analyses of treatment effectiveness for pain, depressive symptoms, and quality of life
por: Kuga A, et al.
Publicado: (2017)

The role of neuroinflammation and neurovascular dysfunction in major depressive disorder
por: Jeon SW, et al.
Publicado: (2018)